ME03377B - Sol i kristalni oblici inhibitora plk-4 - Google Patents

Sol i kristalni oblici inhibitora plk-4

Info

Publication number: ME03377B
Authority: ME; Montenegro
Prior art keywords: hemmer; plk; salt; crystal shapes; shapes
Prior art date: 2013-10-18

Application number

MEP-2019-97A

Other languages

German (de)

English (en)

French (fr)

Inventor

Peter Brent Sampson

Miklos Feher

Heinz W Pauls

Original Assignee

Univ Health Network

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-18

Filing date

2014-10-17

Publication date

2020-01-20

2014-10-17 Application filed by Univ Health Network filed Critical Univ Health Network

2020-01-20 Publication of ME03377B publication Critical patent/ME03377B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MEP-2019-97A 2013-10-18 2014-10-17 Sol i kristalni oblici inhibitora plk-4 ME03377B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361892564P	2013-10-18	2013-10-18
EP14854037.0A EP3057965B1 (en)	2013-10-18	2014-10-17	Salt and crystal forms of plk-4 inhibitor
PCT/CA2014/051001 WO2015054793A1 (en)	2013-10-18	2014-10-17	Salt and crystal forms of plk-4 inhibitor

Publications (1)

Publication Number	Publication Date
ME03377B true ME03377B (me)	2020-01-20

Family

ID=52827507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2019-97A ME03377B (me)	2013-10-18	2014-10-17	Sol i kristalni oblici inhibitora plk-4

Country Status (27)

Country	Link
US (5)	US9884855B2 (me)
EP (1)	EP3057965B1 (me)
JP (1)	JP6492072B2 (me)
KR (3)	KR20220063299A (me)
CN (2)	CN105764899B (me)
AU (1)	AU2014336929B9 (me)
CA (1)	CA2926845C (me)
CY (1)	CY1121484T1 (me)
DK (1)	DK3057965T3 (me)
EA (1)	EA031569B1 (me)
ES (1)	ES2718603T3 (me)
HR (1)	HRP20190564T1 (me)
HU (1)	HUE043194T2 (me)
IL (1)	IL245038B (me)
LT (1)	LT3057965T (me)
ME (1)	ME03377B (me)
MX (1)	MX359069B (me)
NZ (1)	NZ718744A (me)
PL (1)	PL3057965T3 (me)
PT (1)	PT3057965T (me)
RS (1)	RS58413B1 (me)
SG (1)	SG11201602783SA (me)
SI (1)	SI3057965T1 (me)
SM (1)	SMT201900124T1 (me)
TR (1)	TR201902875T4 (me)
TW (1)	TWI659952B (me)
WO (1)	WO2015054793A1 (me)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2756568C (en)	2009-04-06	2018-02-13	University Health Network	Kinase inhibitors and method of treating cancer with same
ES2639757T3 (es)	2010-04-06	2017-10-30	University Health Network	Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales
EA031569B1 (ru)	2013-10-18	2019-01-31	Юниверсити Хелс Нетуорк	Солевые и кристаллические формы ингибитора plk-4
CA3074876A1 (en) *	2017-09-08	2019-03-14	University Health Network	Combination therapies for inhibition of polo-like kinase 4
AU2020264143A1 (en)	2019-04-24	2021-10-28	University Health Network	Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate
WO2021108918A1 (en) *	2019-12-06	2021-06-10	University Health Network	Treatment for acute myeloid leukemia or myelodysplastic syndrome
US20240270722A1 (en)	2021-05-11	2024-08-15	Oric Pharmaceuticals, Inc.	Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2483323A (en) *	1945-08-01	1949-09-27	Kay Fries Chemicals Inc	Method of preparing phenyl ethyl alcohol
US7205328B2 (en)	2002-10-21	2007-04-17	Irm Llc	Oxindoles with anti-HIV activity
DE102005005395A1 (de) *	2005-02-03	2006-08-10	Schering Aktiengesellschaft	Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) *	2006-03-29	2006-05-10	Pliva Istrazivanje I Razvoj D	Pharmaceutically acceptable salts and polymorphic forms
US8227640B2 (en) *	2007-03-23	2012-07-24	Institute Of Bioengineering And Nanotechnology	Palladium catalysts
EP2564850B1 (en) *	2007-09-25	2014-08-13	Takeda Pharmaceutical Company Limited	Polo-like kinase inhibitors
AU2008340991B2 (en)	2007-12-21	2012-02-23	University Health Network	Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
CA2756568C (en)	2009-04-06	2018-02-13	University Health Network	Kinase inhibitors and method of treating cancer with same
US8586598B2 (en) *	2009-04-29	2013-11-19	Nerviano Medical Sciences S.R.L.	CDK inhibitor salts
ES2639757T3 (es)	2010-04-06	2017-10-30	University Health Network	Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales
CA2803446C (en)	2010-07-02	2019-06-04	University Health Network	Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en)	2010-10-13	2012-04-19	University Health Network	Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) *	2010-11-25	2013-09-25	라티오팜 게엠베하	아파티닙의 신규 염 및 다형
EP2766352B1 (en) *	2011-10-12	2018-06-06	University Health Network (UHN)	Indazole compounds as kinase inhibitors and method of treating cancer with same
CN105764515B (zh)	2013-10-18	2020-02-28	大学健康网络	对胰腺癌的治疗
EA031569B1 (ru)	2013-10-18	2019-01-31	Юниверсити Хелс Нетуорк	Солевые и кристаллические формы ингибитора plk-4

2014
- 2014-10-17 EA EA201690755A patent/EA031569B1/ru not_active IP Right Cessation
- 2014-10-17 TR TR2019/02875T patent/TR201902875T4/tr unknown
- 2014-10-17 PL PL14854037T patent/PL3057965T3/pl unknown
- 2014-10-17 RS RS20190269A patent/RS58413B1/sr unknown
- 2014-10-17 ME MEP-2019-97A patent/ME03377B/me unknown
- 2014-10-17 CN CN201480064037.9A patent/CN105764899B/zh active Active
- 2014-10-17 DK DK14854037.0T patent/DK3057965T3/en active
- 2014-10-17 EP EP14854037.0A patent/EP3057965B1/en active Active
- 2014-10-17 HR HRP20190564TT patent/HRP20190564T1/hr unknown
- 2014-10-17 PT PT14854037T patent/PT3057965T/pt unknown
- 2014-10-17 US US15/029,373 patent/US9884855B2/en active Active
- 2014-10-17 JP JP2016524077A patent/JP6492072B2/ja active Active
- 2014-10-17 SI SI201431110T patent/SI3057965T1/sl unknown
- 2014-10-17 WO PCT/CA2014/051001 patent/WO2015054793A1/en not_active Ceased
- 2014-10-17 CN CN202110510808.4A patent/CN113248486A/zh active Pending
- 2014-10-17 KR KR1020227015022A patent/KR20220063299A/ko not_active Ceased
- 2014-10-17 ES ES14854037T patent/ES2718603T3/es active Active
- 2014-10-17 KR KR1020217036751A patent/KR102395737B1/ko active Active
- 2014-10-17 MX MX2016004963A patent/MX359069B/es active IP Right Grant
- 2014-10-17 LT LTEP14854037.0T patent/LT3057965T/lt unknown
- 2014-10-17 SM SM20190124T patent/SMT201900124T1/it unknown
- 2014-10-17 AU AU2014336929A patent/AU2014336929B9/en active Active
- 2014-10-17 SG SG11201602783SA patent/SG11201602783SA/en unknown
- 2014-10-17 HU HUE14854037A patent/HUE043194T2/hu unknown
- 2014-10-17 KR KR1020167012155A patent/KR20160070106A/ko not_active Ceased
- 2014-10-17 CA CA2926845A patent/CA2926845C/en active Active
- 2014-10-17 NZ NZ718744A patent/NZ718744A/en unknown
- 2014-10-17 TW TW103135953A patent/TWI659952B/zh active
2016
- 2016-04-11 IL IL24503816A patent/IL245038B/en active IP Right Grant
2018
- 2018-02-01 US US15/886,104 patent/US10392374B2/en active Active
2019
- 2019-03-22 CY CY20191100336T patent/CY1121484T1/el unknown
- 2019-04-19 US US16/389,119 patent/US10472353B2/en active Active
- 2019-11-06 US US16/675,609 patent/US10919886B2/en active Active
2021
- 2021-02-10 US US17/172,511 patent/US11667627B2/en active Active

Also Published As

Publication number	Publication date
IL245038A0 (en)	2016-05-31
CN105764899A (zh)	2016-07-13
US20160264559A1 (en)	2016-09-15
AU2014336929B9 (en)	2019-03-21
US11667627B2 (en)	2023-06-06
ES2718603T3 (es)	2019-07-03
LT3057965T (lt)	2019-03-12
US10392374B2 (en)	2019-08-27
US20180155335A1 (en)	2018-06-07
PT3057965T (pt)	2019-04-23
US10472353B2 (en)	2019-11-12
US9884855B2 (en)	2018-02-06
NZ718744A (en)	2021-07-30
EA201690755A1 (ru)	2016-09-30
HUE043194T2 (hu)	2019-08-28
MX359069B (es)	2018-09-12
KR20160070106A (ko)	2016-06-17
KR102395737B1 (ko)	2022-05-10
SI3057965T1 (sl)	2019-04-30
HRP20190564T1 (hr)	2019-05-17
PL3057965T3 (pl)	2019-08-30
RS58413B1 (sr)	2019-04-30
EP3057965A4 (en)	2017-05-24
US20200140428A1 (en)	2020-05-07
KR20210137251A (ko)	2021-11-17
IL245038B (en)	2019-11-28
TW201609717A (zh)	2016-03-16
JP2016537326A (ja)	2016-12-01
US10919886B2 (en)	2021-02-16
JP6492072B2 (ja)	2019-03-27
CA2926845A1 (en)	2015-04-23
US20190248775A1 (en)	2019-08-15
CN105764899B (zh)	2021-06-01
CY1121484T1 (el)	2020-05-29
DK3057965T3 (en)	2019-04-01
WO2015054793A1 (en)	2015-04-23
US20210269428A1 (en)	2021-09-02
EP3057965A1 (en)	2016-08-24
KR20220063299A (ko)	2022-05-17
EA031569B1 (ru)	2019-01-31
AU2014336929B2 (en)	2018-11-22
SG11201602783SA (en)	2016-05-30
EP3057965B1 (en)	2019-01-02
TWI659952B (zh)	2019-05-21
CA2926845C (en)	2023-06-13
CN113248486A (zh)	2021-08-13
TR201902875T4 (tr)	2019-03-21
MX2016004963A (es)	2016-06-28
SMT201900124T1 (it)	2019-05-10

Publication	Publication Date	Title
NO2021012I1 (no)	2021-03-18	avapritinib and pharmaceutically acceptable salts thereof
NL301154I2 (nl)	2022-07-18	Mometason of een zout daarvan en olopatadine of een zout daarvan
IL233777B (en)	2018-01-31	Unmapped region visualization
LT3080100T (lt)	2023-02-27	Lizinui specifinės demetilazės-1 inhibitoriai
EP2859441A4 (en)	2016-03-30	PORTABILITY OF APPLICATION DEPLOYMENT IN CLOUD
LT3043785T (lt)	2021-12-10	R-ketamino ir jo druskų vartojimas kaip vaistų
HUE046285T2 (hu)	2020-02-28	Omecamtiv mecarbil sói és eljárás a só elõállítására
FI20135956L (fi)	2015-02-21	Kiinnitin
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
HRP20170840T1 (hr)	2017-09-08	Supstituirani ksantini i metode njihove uporabe
IL238864A0 (en)	2015-06-30	81-facet diamond with 10-heart-and-10-arrow structure inside
NO2024005I1 (no)	2024-01-25	Combination of trifluridine and tipiracil or a salt thereof with bevacizumab
EP2951711A4 (en)	2016-11-09	TIME OF DISPLAY OF AN INTERNET PAGE
LT3077047T (lt)	2019-08-26	Aramcholio druskos
ME03377B (me)	2020-01-20	Sol i kristalni oblici inhibitora plk-4
PL3030519T3 (pl)	2022-05-23	Trójpierścieniowe związki benzoksaborolu i ich zastosowania
EP3525454C0 (en)	2025-02-26	DISPLAY DEVICE
MY165622A (en)	2018-04-18	Amides of 2-amino-4aryl thiazole compounds and their salts
IL235064B (en)	2019-09-26	Methods of producing anamorelin hydrochloride having controlled chloride content
EP2975036A4 (en)	2016-12-14	NOVEL PI POLYAMIDE
IL259184A (en)	2018-07-31	Crystal of flumioxazin
EP3010873C0 (en)	2023-09-13	FLEGMATIZATION OF AN EXPLOSIVE IN AN AQUEOUS SUSPENSION
PL2994479T3 (pl)	2020-02-28	Zmodyfikowana ekspresja prolilo-4-hydroksylazy w physcoitrella patens
ES1078828Y (es)	2013-10-24	Pulsera Anti-Mosquitos
TH1401007310A (th)	2016-09-06	เอไมด์ของสารประกอบ 2-อะมิโน-4-เอริลไธอะโซลและเกลือของสารประกอบดังกล่าว